Your browser doesn't support javascript.
loading
Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios.
Kim, Hannah Yejin; Byashalira, Kenneth C; Heysell, Scott K; Märtson, Anne-Grete; Mpagama, Stellah G; Rao, Prakruti; Sturkenboom, Marieke G G; Alffenaar, Jan-Willem C.
Afiliação
  • Kim HY; Faculty of Medicine and Health, School of Pharmacy, University of Sydney.
  • Byashalira KC; Westmead Hospital.
  • Heysell SK; Marie Bashir Institute for Infectious Diseases, University of Sydney, Sydney, NSW, Australia.
  • Märtson AG; Kibong'oto Infectious Disease Hospital, Moshi, Tanzania.
  • Mpagama SG; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia; and.
  • Rao P; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Sturkenboom MGG; Kibong'oto Infectious Disease Hospital, Moshi, Tanzania.
  • Alffenaar JC; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia; and.
Ther Drug Monit ; 44(1): 3-10, 2022 02 01.
Article em En | MEDLINE | ID: mdl-34686647
ABSTRACT

BACKGROUND:

Therapeutic drug monitoring (TDM) supports personalized treatment. For successful implementation, TDM must have a turnaround time suited to the clinical needs of patients and their health care settings. Here, the authors share their views of how a TDM strategy can be tailored to specific settings and patient groups.

METHODS:

The authors selected distinct scenarios for TDM high-risk, complex, and/or critically ill patient population; outpatients; and settings with limited laboratory resources. In addition to the TDM scenario approach, they explored potential issues with the legal framework governing dose escalation.

RESULTS:

The most important issues identified in the different scenarios are that critically ill patients require rapid turnaround time, outpatients require an easy sampling procedure for the sample matrix and sample collection times, settings with limited laboratory resources necessitate setting-specific analytic techniques, and all scenarios warrant a legal framework to capture the use of escalated dosages, ideally with the use of trackable dosing software.

CONCLUSIONS:

To benefit patients, TDM strategies need to be tailored to the intended population. Strategies can be adapted for rapid turnaround time for critically ill patients, convenient sampling for outpatients, and feasibility for those in settings with limited laboratory resources.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monitoramento de Medicamentos / Anti-Infecciosos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monitoramento de Medicamentos / Anti-Infecciosos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article